Sinclair Pharma will be attending IMCAS Paris once again this year. We added the schedule of all Sinclair Events, Product Symposiums and IMCAS…
Our Group General Counsel and Company Secretary Jayne Burrell talks to The Brief – the number one place for; legal opinions, interviews and updates.
Dr J Few Publication in The Aesthetic Surgery Journal Dr J Few Publication in The Aesthetic Surgery Journal confirms efficacy and patient satisfaction…
Sinclair Pharma plc (AIM:SPH.L) (“Sinclair” or the “Group”), the international aesthetics company, is pleased to announce that it has received regulatory approval of Ellansé® by ANVISA in Brazil.
Pre-Close Trading Update 20% growth in revenue to £45.3million Strong performance across all key brands Return to EBITDA profitanticipated Download Update
Trading Statement 2017 20% growth in revenue to £45.3million Strong performance across all key brands Return to EBITDA profitanticipated Download Report
Please find our 2017 Interim Results meeting recording available to listen on demand.
Interim Results 2017 Presentation 19th September 2017 – Further progress in building a high growth, global pure – play aesthetics business Download Presentation
Interim Results 2017 Interim Results – Strong underlying growth from key products, on track to meet full year guidance for EBITDA profit in…
Trading Update Trading Update for the 6 months to 30 June 2017 Download Trading Update